Mario Negri Institute for Pharmacological Research

CurePSP Awards Latest Pathway and Pipeline Grants and Urso Student Fellowship Grants Looking to Take Advantage of Recent Neuroscience Breakthroughs

Retrieved on: 
Thursday, September 28, 2023

NEW YORK, Sept. 28, 2023 /PRNewswire/ -- CurePSP has awarded its latest Pathway and Pipeline Grants and Urso Student Fellowships, totaling over $422,000. Recipients of the grants are: Dr. Kurt Farrell, assistant professor at the Icahn School of Medicine at Mount Sinai; Dr. Blas Couto, researcher at the Institute of Translational and Cognitive Neuroscience (INCyT) in Buenos Aires; Dr. Luana Fioriti, head of laboratory at the Mario Negri Institute for Pharmacological Research in Milan, alongside Dr. Carmela Tartaglia, associate professor at the University of Toronto and clinician at the Rossy PSP Centre; and Dr. Joseph B. Rayman, assistant professor of medical sciences at Columbia University Irving Medical Center. Recipients of the Urso Student Fellowship Grants are: Hania Qamar (mentor: Dr. Naomi Visanji), a graduate student at the University of Toronto; Hasnat Nuri (mentor: Dr. Stewart Clark), an undergraduate student at SUNY at Buffalo; and Soyeon Park (mentor: Dr. Jonathan Lin), an undergraduate student at Stanford University. The studies will make progress in identifying biomarkers, studying pathways for therapeutics and creating a new database of patients in Argentina.

Key Points: 
  • NEW YORK, Sept. 28, 2023 /PRNewswire/ -- CurePSP has awarded its latest Pathway and Pipeline Grants and Urso Student Fellowships, totaling over $422,000.
  • Recipients of the Urso Student Fellowship Grants are: Hania Qamar (mentor: Dr. Naomi Visanji), a graduate student at the University of Toronto; Hasnat Nuri (mentor: Dr. Stewart Clark), an undergraduate student at SUNY at Buffalo; and Soyeon Park (mentor: Dr. Jonathan Lin), an undergraduate student at Stanford University.
  • The studies will make progress in identifying biomarkers, studying pathways for therapeutics and creating a new database of patients in Argentina.
  • The newest Urso Student Fellowship grants were awarded to students conducting projects that focus on the complex barriers facing research of PSP and CBD.

Autosomal Dominant Polycystic Kidney Disease Market to Surge at a Significant CAGR of 14.5% by 2032 | DelveInsight

Retrieved on: 
Monday, September 19, 2022

LAS VEGAS, Sept. 19, 2022 /PRNewswire/ -- DelveInsight's ADPKD Market Insights report includes a comprehensive understanding of current treatment practices, ADPKD emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].

Key Points: 
  • In addition, the approval and entry of new drugs will change the ADPKD market dynamics in the future.
  • As per DelveInsight estimates, the ADPKDmarket size in the 7MM was approximately USD 1,077 million in 2021.
  • Autosomal dominant polycystic kidney disease also called "adult PKD," is the most common inherited kidney disorder characterized by cyst growth in the kidneys, which increases with disease progression and results in renal failure.
  • Implementing these measures early in the disease should slow the progression of kidney (renal) disease and, to some extent, preserve kidney function.

Promising Clinical Data on Revalesio’s RNS60 Presented at 32nd International Symposium on ALS/MND

Retrieved on: 
Tuesday, December 7, 2021

RNS60 is produced with proprietary technology to uniquely formulate oxygen in saline to address cellular imbalances linked to mitochondrial dysfunction and inflammation.

Key Points: 
  • RNS60 is produced with proprietary technology to uniquely formulate oxygen in saline to address cellular imbalances linked to mitochondrial dysfunction and inflammation.
  • The study enrolled 147 people with ALS who received either RNS60 or placebo over 24 weeks.
  • Data from a multi-year Expanded Access Program (EAP) with RNS60 for people with ALS are also being presented at the conference.
  • Revalesios pipeline is led by RNS60, which is currently in Phase 2 clinical trials for the treatment of ALS and acute ischemic stroke.